Please login to the form below
ESMO
This page shows the latest ESMO news and features for those working in and with pharma, biotech and healthcare.
Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer
The results of that trial, which was presented at last month’s European Society for Medical Oncology (ESMO) Congress, showed that those taking the drug in combination with Abraxane had a
Latest news
-
BMS CEO tackles investor ‘frustrations’ on immuno-oncology
And in the meantime, Opdivo/Yervoy’s lucrative position in first-line kidney cancer is also under threat, with new data at ESMO on Keytruda and Merck KGaA’s PD-L1 ... With comparison to the data that we saw at ESMO, we continue to believe that Opdivo
-
Merck’s Bavencio joins first-line kidney cancer face-off
The JAVELIN Renal 101 study reported at this week’s ESMO conference paired Merck’s immuno-oncology drug Bavencio (avelumab) with Pfizer’s tyrosine kinase inhibitor Inlyta (axitinib), and revealed a
-
Novartis claims a rare win at ESMO for PI3K inhibitor class
Novartis revealed the study was positive in August, but reported the numbers for the first time at ESMO, and they look pretty good; the combination almost doubled PFS from 5.7 ... Alpelisib is the first drug to show a benefit in a genomic subgroup of
-
AZ and Clovis PARP inhibitors show their mettle at ESMO
AZ and Clovis PARP inhibitors show their mettle at ESMO. Lynparza and Rubraca both on track to extend cancer patient reach. ... investigator Kathleen Moore of the University of Oklahoma whilst presenting the results at ESMO.
-
Dynavax is ‘deal-ready’ after solid ESMO data; analyst
Dynavax is ‘ deal-ready’ after solid ESMO data; analyst. Contrasting results for two novel immunotherapies. ... showing for the big pharma company’s rival immune-boosting approach, which also made its clinical debut at ESMO.
More from news
Approximately 10 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Biologic or biosimilar: what are prescribers thinking?
independent organisations such as ESMO, which recently published a paper supporting biosimilars as an option for sustainable cancer treatment.
-
Accelerating innovation
Phase II results from its CABOSUN trial, in which it was compared with Sutent in previously untreated advanced RCC, were released at this year’s European Society for Medical Oncology (ESMO) ... As the ESMO meeting began, Ipsen received the news that
-
Charting a course for expansion
When I met him at the annual European Society for Medical Oncology (ESMO) meeting in Copenhagen last month he explained how international expansion and oncology were key to Ipsen's plans. ... In Copenhagen, Ipsen's ESMO focus was on the CABOSUN study,
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Why patient education is important in oncology
Why patient education is important in oncology. We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.
-
FALCON trial of fulvestrant for advanced breast cancer
FALCON trial of fulvestrant for advanced breast cancer. The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer. Summary/transcript. Prof. Matthew Ellis from the Baylor College of Medicine
-
How pembrolizumab will change the management of advanced lung cancer
How pembrolizumab will change the management of advanced lung cancer. The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by VJOncology Editorial Board Member Dr Martin Reck of
-
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
Dr Choueiri, who presented the results at ESMO 2016, explains, they also had an early look at overall survival (OS), which is not significant yet but trending in the right direction.
-
No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer
We talked to Dr Ursula Matulonis of the Dana-Farber Cancer Institute, who co-authored the abstract presented at ESMO.
More from PMHub
Approximately 8 fully matching, plus 0 partially matching documents found.
Featured jobs
-
Account Director
-
£48, 000 - £60, 000
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
-
Associate Medical Director
-
Highly Competitive
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
- Senior Account Executive, London, Medical Communications
-
Excellent package
- Senior Systematic Review Analyst - Oxford
-
Negotiable
-
Senior Medical Writer
-
Great salary and benefits
- Events Manager – Med Comms – Surrey
-
Salary TBC
-
Senior Medical Writer
-
Competitive Salary
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
-
Senior Account Manager
-
Negotiable
-
New Business Director - PR
-
Competitive Salary and benefits
-
Medical Writers
-
Competitive Salary and Benefits
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
Subscribe to our email news alerts
- Entering the era of digital trials
- Confocal Microscope Market to Witness Notable Revenue Growth in North America Owing to Increasing Spending on R&D Initiatives in the Region
- Confocal Microscope Market to Witness Notable Revenue Growth in North America Owing to Increasing Spending on R&D Initiatives in the Region
- Carpal Tunnel Release Systems Market to reach a market valuation worth US$ 839.1 Mn by the end of 2028
- Digital Radiography Detectors Market to reach a valuation of US$ 2,713.7 Mn by 2026, exhibiting a promising 6.1% CAGR during 2018-2026.
- Analgesics Market is anticipated to reach a whopping US$ 79 Bn by 2028 end
PMHub
mXm Medical Communications
mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...
Latest intelligence
- Innovation in merger control and the impact on the pharmaceutical sector
- Is focusing on pipeline products enough to assess regulatory risks?...
- Nudge-nudge, think-think
- Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
- Quality in Care Diabetes 2018: the best in innovative diabetes care
- Awards highlight new evidence-based approaches to improving care...
Quick links
Infographics
